The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
“The journey through these phases varies for each person and may cycle, depending on the response to treatment and external stressors,” says Michael Kane, MD, a psychiatrist and the chief ...
Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...
Psychosis affects one's physical, psychological, social, and existential health. Mental health recovery often involves a ...
Scientists have known for decades that the classic symptoms of schizophrenia, such as jumping to conclusions or difficulty ...